Our study suggests that targeting hyperactive Akt resulting from Aldob deficiency through directly inhibiting Akt kinase or reactivating PP2A phosphatase activity may serve as an antitumor treatment for HCC. Here, AKT1 is linked to hepatocellular carcinoma.